Navigation Links
WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering

SHANGHAI, China, April 4, 2008 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech"), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it has filed a Registration Statement on Form F-1 with the Securities and Exchange Commission for a proposed follow-on and secondary public offering of American Depositary Shares. The securities to be sold in the proposed offering will include shares to be issued and sold by the company as well as shares to be sold by certain shareholders.

(Logo: )

Credit Suisse Securities (USA) LLC and JP Morgan Securities, Inc. will act as lead underwriters and joint book-runners in the offering. Copies of the preliminary prospectus, when available, may be obtained by contacting Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue 1B, New York, NY 10010; phone 1-800-221-1037; or by contacting JP Morgan Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245; phone 1-866-430-0686.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device research and development, or R&D, outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the R&D process to pharmaceutical, biotechnology and medical device companies. WuXi PharmaTech's services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing cost-effective and efficient outsourcing solutions. For more information, please visit


Sherry Shao

WuXi PharmaTech

Tel: +86 (21) 5046-4002

SOURCE WuXi PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
2. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
3. WuXi PharmaTech Completes Acquisition of AppTec
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
6. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
9. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
10. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
11. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
Post Your Comments:
(Date:11/30/2015)... - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced ... to its Board of Directors to replace Dr. Peter ... of experience as co-founder of Resverlogix, with expertise in the ... --> Dr. Wong remarked, "I am very ... long standing expertise in epigenetics and the advanced stage of ...
(Date:11/30/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... Genomics, Inc., a leading genome informatics company offering highly ... The San Diego -based company has ... and Co-founder, Ashley Van Zeeland , Ph.D., who is ... of the deal were not disclosed. ...
(Date:11/30/2015)... 30, 2015  AbbVie, is introducing Good Morning ... a daily routine for managing the life-long condition of ... affect the way the body absorbs it so resources ... daily routine are important. The goal of the new ... manage their hypothyroidism by establishing a daily routine, spirit ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 BrainStorm Cell ... of adult stem cell technologies for neurodegenerative diseases, today announced ... awarded an additional grant of approximately $735,000 from ... grant, the second this year, brings the total awarded by ... (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
Breaking Biology News(10 mins):